What is Spatial Genomics?
Spatial Genomics operates at the intersection of advanced microscopy and high-throughput genomics, providing researchers with the tools to visualize and quantify biological states within intact tissues. The company's core technology enables the simultaneous assaying of gene expression, protein expression, and epigenomic states, effectively bridging the gap between traditional histology and modern molecular biology. By cataloging not just individual cell states but also the complex interactions and influences within cellular neighborhoods, Spatial Genomics empowers discovery in precision medicine, drug development, and fundamental biological research. This holistic approach to spatial analysis is essential for understanding disease progression and therapeutic response in a clinical context.
How much funding has Spatial Genomics raised?
Spatial Genomics has raised a total of $56M across 1 funding round:
Series A
$56M
Series A (2022): $56M with participation from Fulgent and 12 West Capital Management
Key Investors in Spatial Genomics
Fulgent
A premier, full-service genomic testing company focused on transforming patient care in oncology, rare diseases, and reproductive health through a foundational technology platform.
12 West Capital Management
An investment firm providing strategic capital to high-growth companies, often focusing on long-term value creation within the healthcare and technology sectors.
What's next for Spatial Genomics?
With the recent strategic investment, Spatial Genomics is poised to scale its operational capacity and expand its commercial footprint within the global life sciences market. The company is expected to prioritize the refinement of its multiplexed analysis platform, aiming to reduce barriers to adoption for academic and clinical research institutions. Furthermore, the integration of these advanced spatial insights into drug development pipelines represents a significant growth vector. As the firm continues to mature, the focus will likely shift toward establishing strategic partnerships with diagnostic providers and pharmaceutical entities, ultimately aiming to standardize spatial biology as a cornerstone of modern precision medicine and patient-centric care.
See full Spatial Genomics company page
